Evidence Based Oncology: Future of Incentive-Driven Pathway Adherence

HRA’s Oncology Pathways: Future of Incentive-Driven Adherence explores recent decisions by payers to provide financial incentives to oncologists to follow their evidence-based treatment pathways. This creates an opportunity for pharmaceutical companies to understand the implications this may have on current brand utilization and future prescribing trends.

Research Topics:

  • Key attributes driving decision making among payers about the perceived value of clinical pathways on patients and cost of care
  • Implication of clinical pathways use on select types of tumors, the expected expansion trends, biomarker testing, and how clinical pathways impact clinical trial referrals
  • Market forces driving the use of clinical pathways in oncology

Applications

  • Understand how pathways are developed and the role of oncologists, payers, and third-party vendors.
  • Map out goals for providers to follow clinical pathways.
  • Gauge the receptivity of oncologists to the use of clinical pathways and the impact of incentives.
  • Determine the impact of clinical pathways on patient care and implications for manufacturers.

Find syndicated research too general? Tailor our findings to your needs!

  • Use this as a start to follow-up custom research
  • Custom reporting and analysis focused on your team’s issues
Price: $695.00
PURCHASE STUDY
×
My Cart
Subtotal $0.00
Checkout
Copyright HRA Data Driven Intelligence 1974-2018 HRA Data Driven Intelligence, LLC. All rights Reserved.
^